Top

Published in:

01-12-2015 | Original Article

Controversial evidence for the use of HistoScanning™ in the detection of prostate cancer

Authors: Jonas Schiffmann, Lukas Manka, Katharina Boehm, Sami-Ramzi Leyh-Bannurah, Pierre I. Karakiewicz, Markus Graefen, Peter Hammerer, Georg Salomon

Published in: World Journal of Urology | Issue 12/2015

Abstract

Introduction

Given the growing body of literature since first description of HistoScanning™ in 2008, there is an unmet need for a contemporary review.

Evidence acquisition

Studies addressing HistoScanning™ in prostate cancer (PCa) were considered to be included in the current review. To identify eligible reports, we relied on a bibliographic search of PubMed database conducted in January 2015.

Evidence synthesis

Twelve original articles were available to be included in the current review. The existing evidence was reviewed according to the three following topics: prediction of final pathology at radical prostatectomy, prediction of disease stage and application at prostate biopsy.

Conclusions

High sensitivity and specificity for HistoScanning™ to predict cancer foci ≥0.5 ml at final pathology were achieved in the pilot study. These results were questioned, when HistoScanning™ derived tumor volume does not correlate with final pathology results. Additionally, HistoScanning™ was not able to provide reliable staging information according to neither extraprostatic extension, nor seminal vesicle invasion prior to radical prostatectomy. Controversy data also exist according to the use of HistoScanning™ at prostate biopsy. Specifically, most encouraging results were recorded in a small patient cohort. Conversely, HistoScanning™ achieved poor prediction of positive biopsies, when relying on larger studies. Finally, the combination of HistoScanning™ and conventional ultrasound achieved lower detection rates than systematic biopsy. Currently, evidence is at best weak and questions whether HistoScanning™ might improve the detection of PCa.

Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, Wirth M, Mottet N (2013) Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol 64(3):347–354. doi:10.1016/j.eururo.2013.06.051 CrossRefPubMed

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP III, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M (2014) Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 12(9):1211–1219 quiz 1219PubMed

Salomon G, Schiffmann J (2014) Real-time elastography for the detection of prostate cancer. Curr Urol Rep 15(3):392. doi:10.1007/s11934-013-0392-z CrossRefPubMed

Boehm K, Salomon G, Beyer B, Schiffmann J, Simonis K, Graefen M, Budaeus L (2014) Shear wave elastography for localization of prostate cancer lesions and assessment of elasticity thresholds: implications for targeted biopsies and active surveillance protocols. J Urol. doi:10.1016/j.juro.2014.09.100 PubMed

Braeckman J, Autier P, Garbar C, Marichal MP, Soviany C, Nir R, Nir D, Michielsen D, Bleiberg H, Egevad L, Emberton M (2008) Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int 101(3):293–298. doi:10.1111/j.1464-410X.2007.07232.x CrossRefPubMed

Valerio M, Donaldson I, Emberton M, Ehdaie B, Hadaschik BA, Marks LS, Mozer P, Rastinehad AR, Ahmed HU (2014) Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review. Eur Urol. doi:10.1016/j.eururo.2014.10.026 PubMedCentral

Loch T (2007) Computerized transrectal ultrasound (C-TRUS) of the prostate: detection of cancer in patients with multiple negative systematic random biopsies. World J Urol 25(4):375–380. doi:10.1007/s00345-007-0181-8 CrossRefPubMed

US National Institutes of Health. http://www.clinicaltrials.gov

Braeckman J, Autier P, Soviany C, Nir R, Nir D, Michielsen D, Treurnicht K, Jarmulowicz M, Bleiberg H, Govindaraju S, Emberton M (2008) The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int 102(11):1560–1565. doi:10.1111/j.1464-410X.2008.07878.x CrossRefPubMed

10.

Simmons LA, Autier P, Zat’ura F, Braeckman J, Peltier A, Romic I, Stenzl A, Treurnicht K, Walker T, Nir D, Moore CM, Emberton M (2012) Detection, localisation and characterisation of prostate cancer by prostate HistoScanning™. BJU Int 110(1):28–35. doi:10.1111/j.1464-410X.2011.10734.x CrossRefPubMed

11.

Javed SCE, Beveridge S, Bott S, Eden C, Langley S (2013) Does prostate Histoscanning™ accurately identify prostate cancer, measure tumour volume and assess pathological stage prior to radical prostatectomy? J Clin Urol. doi:10.1177/2051415813489682

12.

Macek P, Barret E, Sanchez-Salas R, Galiano M, Rozet F, Ahallal Y, Gaya JM, Durant M, Mascle L, Giedelman C, Lunelli L, Validire P, Nesvadba M, Cathelineau X (2013) Prostate Histoscanning in clinically localized biopsy proven prostate cancer: an accuracy study. J Endourol. doi:10.1089/end.2013.0419 PubMed

13.

Schiffmann J, Fischer J, Tennstedt P, Beyer B, Bohm K, Michl U, Graefen M, Salomon G (2013) Comparison of prostate cancer volume measured by HistoScanning and final histopathological results. World J Urol. doi:10.1007/s00345-013-1211-3 PubMed

14.

D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974CrossRefPubMed

15.

Salomon G, Spethmann J, Beckmann A, Autier P, Moore C, Durner L, Sandmann M, Haese A, Schlomm T, Michl U, Heinzer H, Graefen M, Steuber T (2013) Accuracy of HistoScanning for the prediction of a negative surgical margin in patients undergoing radical prostatectomy. BJU Int 111(1):60–66. doi:10.1111/j.1464-410X.2012.11396.x CrossRefPubMed

16.

Schiffmann J, Beyer B, Fischer J, Tennstedt P, Boehm K, Michl U, Graefen M, Salomon G (2014) Histoscanning has low sensitivity and specificity for seminal vesicle invasion. Urology 84(5):1168–1171. doi:10.1016/j.urology.2014.06.050 CrossRefPubMed

17.

Schlomm T, Tennstedt P, Huxhold C, Steuber T, Salomon G, Michl U, Heinzer H, Hansen J, Budaus L, Steurer S, Wittmer C, Minner S, Haese A, Sauter G, Graefen M, Huland H (2012) Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients. Eur Urol 62(2):333–340. doi:10.1016/j.eururo.2012.04.057 CrossRefPubMed

18.

Nunez-Mora C, Garcia-Mediero JM, Patino P, Orellana C, Garrido A, Rojo A, Rendon D (2013) Utility of Histoscanning prior to prostate biopsy for the diagnosis of prostate adenocarcinoma. Actas Urol Esp. doi:10.1016/j.acuro.2013.01.003 PubMed

19.

Javed S, Chadwick E, Edwards AA, Beveridge S, Laing R, Bott S, Eden C, Langley S (2013) Does HistoScanning play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies. BJU Int. doi:10.1111/bju.12568 PubMed

20.

Schiffmann J, Tennstedt P, Fischer J, Tian Z, Beyer B, Boehm K, Sun M, Gandaglia G, Michl U, Graefen M, Salomon G (2014) Does HistoScanning predict positive results in prostate biopsy? A retrospective analysis of 1,188 sextants of the prostate. World J Urol 32(4):925–930. doi:10.1007/s00345-014-1330-5 CrossRefPubMed

21.

Sivaraman A, Sanchez-Salas R, Barret E, Macek P, Validire P, Galiano M, Rozet F, Cathelineau X (2014) Prostate histoscanning true targeting guided prostate biopsy: initial clinical experience. World J Urol. doi:10.1007/s00345-014-1434-y PubMed

22.

Schiffmann J, Connan J, Salomon G, Boehm K, Beyer B, Schlomm T, Tennstedt P, Sauter G, Karakiewicz PI, Graefen M, Huland H (2015) Tumor volume in insignificant prostate cancer: increasing threshold gains increasing risk. Prostate 75(1):45–49. doi:10.1002/pros.22889 CrossRefPubMed

23.

Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH (2011) The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 60(2):291–303. doi:10.1016/j.eururo.2011.05.006 CrossRefPubMed

24.

Wirth M, Weißbach L, Ackermann R, Alberti W, Albrecht C, Göckel-Beining B, Fröhner M, Hinkelbein W, Miller K, Rübben H (2011) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. AWMF, Düsseldorf

Title: Controversial evidence for the use of HistoScanning™ in the detection of prostate cancer
Authors: Jonas Schiffmann
Lukas Manka
Katharina Boehm
Sami-Ramzi Leyh-Bannurah
Pierre I. Karakiewicz
Markus Graefen
Peter Hammerer
Georg Salomon
Publication date: 01-12-2015
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 12/2015
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-015-1555-y

At a glance: The STEP trials

Springer Medicine

Controversial evidence for the use of HistoScanning™ in the detection of prostate cancer

Abstract

Introduction

Evidence acquisition

Evidence synthesis

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Evidence acquisition

Evidence synthesis

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2015

Loss of AQP3 protein expression is associated with worse progression-free and cancer-specific survival in patients with muscle-invasive bladder cancer

Histopathology and prognosis of de novo bladder tumors following solid organ transplantation

Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma

Naftopidil versus flopropione as medical expulsive therapy for distal ureteral stones: results of a randomized, multicenter, double-blind, controlled trial

Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta

Impact of 2004 ISUP/WHO classification on bladder cancer grading